Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary OXiGENE Announces Positive New Preclinical Safety and Efficacy Data for CA4P at AACR
OXiGENE Announces Positive New Preclinical Safety and Efficacy Data for CA4P at AACR WALTHAM, Mass.--(BUSINESS WIRE)--April 19, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN): -CA4P in Combination Treatment Causes Complete Remissions in Anaplastic Thyroid Preclinical Model- -Safety Profile for
View HTML
Toggle Summary OXiGENE Announces New Preclinical Data Presented at AACR Supporting Development of Lead Vascular Targeting Agents; OXi4503 Shows Promising Preclinical Efficacy Data in Colorectal Tumors
OXiGENE Announces New Preclinical Data Presented at AACR Supporting Development of Lead Vascular Targeting Agents; OXi4503 Shows Promising Preclinical Efficacy Data in Colorectal Tumors CA4P's Safety Profile Further Characterized WALTHAM, Mass., Apr 18, 2005 (BUSINESS WIRE) -- OXiGENE, Inc.
View HTML
Toggle Summary OXiGENE to Webcast First-Quarter 2005 Financial Results Conference Call April 27; Live Webcast to be Available at www.oxigene.com
OXiGENE to Webcast First-Quarter 2005 Financial Results Conference Call April 27; Live Webcast to be Available at www.oxigene.com WALTHAM, Mass.--(BUSINESS WIRE)--April 15, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's
View HTML
Toggle Summary OXiGENE Announces Presentations on Lead Vascular Targeting Agents at American Association of Cancer Research
OXiGENE Announces Presentations on Lead Vascular Targeting Agents at American Association of Cancer Research Seven Poster Presentations on CA4P and OXi4503 at AACR WALTHAM, Mass.--(BUSINESS WIRE)--April 13, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the topics and schedules for
View HTML
Toggle Summary OXiGENE to Present at Lehman Brothers Eighth Annual Global HealthCare Conference: April 1st Presentation Available via Live Webcast
OXiGENE to Present at Lehman Brothers Eighth Annual Global HealthCare Conference: April 1st Presentation Available via Live Webcast WALTHAM, Mass.--(BUSINESS WIRE)--March 30, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target
View HTML
Toggle Summary OXiGENE, Inc. Adopts Stockholder Rights Plan
OXiGENE, Inc. Adopts Stockholder Rights Plan WALTHAM, Mass.--(BUSINESS WIRE)--March 25, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today that its Board of Directors has adopted a Stockholder Rights Plan (the "Rights Plan") that is designed to strengthen the ability of the Board of
View HTML
Toggle Summary OXiGENE Announces Sale of $15 Million of Common Stock
OXiGENE Announces Sale of $15 Million of Common Stock WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that the Company will receive gross proceeds of $15 million from the sale of 3,336,117 shares of its common stock, pursuant to OXiGENE's
View HTML
Toggle Summary OXiGENE to Present at 3rd International Symposium on Targeted Anticancer Therapies
OXiGENE to Present at 3rd International Symposium on Targeted Anticancer Therapies WALTHAM, Mass.--(BUSINESS WIRE)--March 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and
View HTML
Toggle Summary OXiGENE to Present at Wells Fargo Securities 2005 HealthCare Conference: March 2nd Presentation Available via Live Webcast
OXiGENE to Present at Wells Fargo Securities 2005 HealthCare Conference: March 2nd Presentation Available via Live Webcast WALTHAM, Mass.--(BUSINESS WIRE)--March 1, 2005--OXiGENE, Inc. (NASDAQ:OXGN, XSSE:OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood
View HTML
Toggle Summary OXiGENE Reports Fourth-Quarter and Year-End 2004 Financial Results
OXiGENE Reports Fourth-Quarter and Year-End 2004 Financial Results WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 25, 2005--Accomplishments in 2004: Initiated two new clinical oncology trials with CA4P; CA4P now studied in seven clinical oncology trials Initiated a Phase II trial of CA4P in myopic macular
View HTML